Mebendazole for Lung Cancer: Mouse Study, Not a Treatment

An Instagram post from @hashem.alghaili, posted around October 14, 2026, says a deworming drug, mebendazole, combined with the targeted drug gefitinib makes drug-resistant, EGFR-mutant non-small cell lung cancer vulnerable again. It says "preclinical animal models" showed significantly delayed tumor growth. It cites "Satyam SM (2026), Repurposing anthelmintic mebendazole in combination with targeted therapy against drug-resistant lung cancer," in PLOS ONE. A commenter says the paper they found used only cell lines, with no animal work, and that they could not find the cited paper.

View the original post

The quote above is the only caption wording we captured. The rest of that paragraph is our summary of the post.

Does the cited paper exist?

We could not find a paper with the title given in the post. We did find two real PLOS ONE papers on this topic from the same group. Shakta Mani Satyam is an author on both, but not the first author.

Paper 1, December 16, 2025. El-Tanani M, Satyam SM, et al., "Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer cell lines," PLOS ONE 20(12): e0338027. The page we read describes only cultured cells (a lung line, A549, and a breast cancer line). It describes no animal work. The authors say the claims need further validation, including in living animals. This is probably what the commenter found.

Paper 2, October 8, 2026. El-Tanani M, Satyam SM, Prabhakar S, et al., "Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer," PLOS ONE 21(10): e0360164. Its PubMed record lists both resistant lung cancer cells and a mouse model. This is the study the post appears to describe.

So the commenter is right about the earlier paper, and the post is right that animals were used in the newer one. The post's citation matches neither title, which is why it is hard to find.

What's real

In Paper 2, the models were one gefitinib-resistant, EGFR-mutant human lung cancer cell line (HCC827 GR5) and mice that had tumors grown from those cells.

In cells. Gefitinib alone left about 92.7% of cells alive. Mebendazole alone at 0.1 micromolar left about 79.7%, and at 0.5 micromolar about 29.7%. Gefitinib 1 micromolar plus mebendazole 0.1 micromolar left about 37.7%. The combination also increased DNA damage markers.

In mice. Median tumor doubling time rose from about 6.2 days in untreated mice to about 25 days with both drugs, a growth delay of about 18.8 days. The authors report this as statistically significant (p < 0.01) and report no substantial toxicity. News coverage of the paper reports 10.3 days with mebendazole alone and 15.5 days with gefitinib alone. The tumors were not eliminated. The study ran 40 days.

The paper's own conclusion is that mebendazole could be explored as an add-on to overcome gefitinib resistance. In news coverage, the lead author said the team is encouraged but that further preclinical validation is needed.

What's missing or wrong

It is not a human result. Cells in a dish and mice with tumors under the skin are early-stage models. Many drugs that work this way fail in people.

It is one model. Only one resistant cell line and one mouse tumor type were used. News coverage says the results may not apply to other lung cancers and that resistance to osimertinib, a newer EGFR drug, has not been tested.

Unanswered questions. The authors could not confirm whether mebendazole restores sensitivity to gefitinib or simply adds damage. Coverage also notes that mebendazole absorption by mouth varies, so the right dose in people is unknown. The PubMed abstract gives few details on the animal work, such as numbers per group, and news reports differ on those details. We did not read the full paper, so we do not state them.

The post's wording. "Significantly delayed" is fair for tumor growth. "Vulnerable" goes further than a slower-growing tumor in mice shows.

What is known about people

We searched ClinicalTrials.gov for mebendazole and lung cancer. We found no registered lung cancer trial of mebendazole. Our search was limited and may have missed some. Trials of mebendazole in other cancers do exist, including a phase 3 trial in colon cancer (NCT03925662, recruiting) and phase 1 trials in brain tumors. A trial in another cancer says little about lung cancer.

For repurposed anti-parasite drugs more broadly, we did not find a page from the National Cancer Institute (NCI) that addresses mebendazole, ivermectin or fenbendazole by name. NCI's general guidance on unproven therapies says some "do not work, may be harmful, or could interact negatively with your medicines," and says to tell your doctor or nurse about anything you use. Our earlier pages cover fenbendazole, ivermectin, a fenbendazole remission claim and an ivermectin remission claim.

What to do with this

Do not start mebendazole, or any dewormer, on your own for lung cancer. Mebendazole is approved for worm infections, not for cancer. A dose that works in mice may be wrong or unsafe in a person, and it could interact with your cancer medicines. Stopping or delaying a treatment that works to try an unproven one can cost time you may not get back.

If you have EGFR-mutant lung cancer and your treatment has stopped working, ask your oncology team about proven next steps and about clinical trials you may qualify for. Our guide to EGFR-mutated non-small cell lung cancer is a starting point. To read results like these, see Clinical Trial Results: What They Mean.

If you have a fever of 100.4 F (38 C) or higher during cancer treatment, call your care team right away. For emergencies, call 911.

Sources

• Instagram post (@hashem.alghaili): instagram.com
• El-Tanani M, et al., "Dual targeting of EGFR signaling and microtubule dynamics...," PLOS ONE 2026 (PubMed record; DOI 10.1371/journal.pone.0360164): pubmed.ncbi.nlm.nih.gov
• El-Tanani M, et al., "Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib...," PLOS ONE 2025 (PubMed record): pubmed.ncbi.nlm.nih.gov
• ScienceAlert, "A Cheap Deworming Pill Could Help Beat Drug-Resistant Lung Cancer," October 13, 2026: sciencealert.com
• Medical Xpress, "Common deworming drug helps restore lung cancer's sensitivity to targeted therapy in mice," October 14, 2026: medicalxpress.com
• ClinicalTrials.gov search for mebendazole and cancer: clinicaltrials.gov
• National Cancer Institute, "Complementary and Alternative Medicine": cancer.gov

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used PubMed records and two news reports that we opened on October 31, 2026. We did not open the full text of the PLOS ONE papers, so animal numbers and methods come from the abstract and news coverage and are limited to what they agree on. The journal's own page for the 2026 paper was not opened. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.